RET (Y806C)

RET · Variant type: point · HGVS: p.Y806C

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	99.4%	0.6%	93.43
2	Selpercatinib	99.1%	0.9%	96.72
3	Canertinib	98.4%	1.6%	96.49
4	Tivozanib	97.0%	3.0%	92.42
5	Fedratinib	95.2%	4.8%	96.21
6	Entrectinib	90.0%	10.0%	93.69
7	Alpelisib	89.0%	11.0%	97.22
8	Sorafenib	88.9%	11.1%	96.72
9	Apatinib	87.7%	12.3%	97.73
10	Tenalisib	86.4%	13.6%	97.98
11	Gilteritinib	61.1%	38.9%	88.97
12	Futibatinib	58.6%	41.4%	98.48
13	Quizartinib	48.6%	51.4%	99.50
14	Ripretinib	43.2%	56.8%	92.95
15	Vandetanib	32.0%	68.0%	95.74
16	Repotrectinib	26.1%	73.9%	84.21
17	Avapritinib	19.7%	80.3%	97.73
18	Erdafitinib	19.3%	80.7%	95.71
19	Defactinib	17.1%	82.9%	92.68
20	Sunitinib	14.0%	86.0%	91.73
21	Pexidartinib	8.3%	91.7%	99.49
22	Rabusertib	7.6%	92.4%	98.74
23	Mobocertinib	5.6%	94.4%	97.22
24	Neratinib	5.4%	94.6%	93.18
25	Gedatolisib	4.2%	95.8%	99.75

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	99.4%	100.0%	-0.6%
Selpercatinib	99.1%	100.0%	-0.9%
Canertinib	98.4%	—	—
Tivozanib	97.0%	99.7%	-2.8%
Fedratinib	95.2%	99.9%	-4.6%
Entrectinib	90.0%	99.6%	-9.6%
Alpelisib	89.0%	99.6%	-10.6%
Sorafenib	88.9%	94.0%	-5.1%
Apatinib	87.7%	—	—
Tenalisib	86.4%	98.5%	-12.1%
Gilteritinib	61.1%	100.0%	-38.9%
Futibatinib	58.6%	97.7%	-39.1%
Quizartinib	48.6%	—	—
Ripretinib	43.2%	—	—
Vandetanib	32.0%	98.6%	-66.6%
Repotrectinib	26.1%	—	—
Avapritinib	19.7%	—	—
Erdafitinib	19.3%	94.7%	-75.4%
Defactinib	17.1%	—	—
Sunitinib	14.0%	97.2%	-83.2%
Pexidartinib	8.3%	—	—
Rabusertib	7.6%	—	—
Mobocertinib	5.6%	—	—
Neratinib	5.4%	—	—
Gedatolisib	4.2%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 26.9ms